Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
ASML
ASML
$691B
| $69.2M | 0.09% |
531,050
-153,999
| -22% | -$20.4M |
|
277
CME Group
CME
$93.2B
| $69M | 0.09% |
550,895
+469,900
| +580% | +$56.2M |
|
278
Snap-on
SNA
$21.3B
| $69M | 0.09% |
436,600
+413,800
| +1,815% | +$67.7M |
|
|
BBBY
279
DELISTED
Bed Bath & Beyond Inc
BBBY
| $68.5M | 0.09% |
+2,254,860
| New | +$81.5M |
|
280
Willis Towers Watson
WTW
$31.8B
| $68.3M | 0.09% |
469,320
+202,300
| +76% | +$28.3M |
|
281
Sony
SONY
$138B
| $67.6M | 0.09% |
8,854,130
+3,184,630
| +56% | +$22.6M |
|
|
FL
282
DELISTED
Foot Locker
FL
| $67.6M | 0.09% |
1,372,300
+1,297,900
| +1,744% | +$84.2M |
|
283
Exelon
EXC
$46.2B
| $67M | 0.09% |
+2,605,230
| New | +$66.3M |
|
284
PetMed Express
PETS
$42.3M
| $66.9M | 0.09% |
1,647,400
-138,915
| -8% | -$4.3M |
|
285
AB InBev
BUD
$159B
| $65.7M | 0.08% |
595,500
+412,600
| +226% | +$47.2M |
|
286
Synopsys
SNPS
$78.7B
| $65.7M | 0.08% |
900,834
+438,100
| +95% | +$32.2M |
|
|
CZZ
287
DELISTED
Cosan Limited
CZZ
| $65.3M | 0.08% |
10,185,699
+1,947,500
| +24% | +$14.3M |
|
288
Essex Property Trust
ESS
$18.2B
| $64.5M | 0.08% |
250,900
+136,900
| +120% | +$34.4M |
|
|
AHL
289
DELISTED
ASPEN Insurance Holding Limited
AHL
| $64.5M | 0.08% |
1,293,800
+232,110
| +22% | +$11.8M |
|
290
Adobe
ADBE
$105B
| $64.3M | 0.08% |
454,700
+334,600
| +279% | +$45.8M |
|
291
Marvell Technology
MRVL
$191B
| $64.2M | 0.08% |
3,886,158
+2,741,914
| +240% | +$44.3M |
|
292
Public Service Enterprise Group
PEG
$37.5B
| $64.2M | 0.08% |
1,492,600
+1,016,300
| +213% | +$44.9M |
|
|
WAGE
293
DELISTED
WageWorks, Inc.
WAGE
| $64.1M | 0.08% |
954,100
+128,800
| +16% | +$9.15M |
|
294
Euronet Worldwide
EEFT
$2.64B
| $64M | 0.08% |
732,545
-103,500
| -12% | -$8.87M |
|
295
Post Holdings
POST
$3.56B
| $64M | 0.08% |
1,259,072
-629,078
| -33% | -$33.9M |
|
296
Ormat Technologies
ORA
$7.04B
| $63.7M | 0.08% |
1,085,257
+164,100
| +18% | +$9.63M |
|
|
ETFC
297
DELISTED
E*Trade Financial Corporation
ETFC
| $63.5M | 0.08% |
1,669,240
+871,100
| +109% | +$30.8M |
|
298
Universal Health Services
UHS
$9.94B
| $63.1M | 0.08% |
+517,200
| New | +$61.6M |
|
299
Charter Communications
CHTR
$18.8B
| $62.6M | 0.08% |
185,961
-46,897
| -20% | -$15.6M |
|
300
WD-40
WDFC
$3.13B
| $62.6M | 0.08% |
567,185
-4,115
| -0.7% | -$438K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.